#SaludTues Tweetchat 4/28: How to Ensure Diversity in Research during Coronavirus

by

Tweetchat
Latino scientist microscope clinical trial study research
Share On Social!

Fewer than 5% of Latinos participate in federal clinical trials.

That gives researchers less chance to find treatments that work for this population. Latinos suffer a heavier burden of coronavirus, obesity, and certain cancers.

How are we going to make sure new treatments─such as a COVID-19 vaccine─work as well for Latinos and other people of color?

Let’s use #SaludTues on Tuesday, April 28, 2020, to discuss how to ensure diversity and inclusion of people of color in research amid the COVID-19 pandemic!

  • WHAT: #SaludTues Tweetchat: How to Ensure Diversity in Research during Coronavirus
  • TIME/DATE: 1-2 p.m. ET (Noon-1 p.m. CT), Tuesday, April 28, 2020
  • WHERE: On Twitter with hashtag #SaludTues
  • HOST: @SaludAmerica
  • CO-HOSTS: UnidosUS (@WeAreUnidosUS); League of United Latin American Citizens (@LULAC); ACCESS (@ACCESS1971); Black Women’s Health Imperative (@blkwomenshealth); Asian & Pacific Islander American Health Forum (@APIAHF)
  • HASHTAG: #SaludTues
  • OPTIONAL HASHTAGS: #COVID19 #joinallofus

We’ll open the floor to your comments, tips, and stories as we explore:

  • What is the state of diversity in research studies?
  • How do families of color experience challenges in participating in research?
  • What ways can we improve minority participation in research?

Be sure to use the hashtag #SaludTues to follow the conversation on Twitter and share your strategies, stories, and resources to explore how to stimulate minority participation in clinical trials!

#SaludTues is a health equity tweetchat especially focused on the Latino population at 12p CT/1p ET every Tuesday hosted by the @SaludAmerica program at the Institute for Health Promotion Research at UT Health San Antonio.

Explore More:

Healthcare Access

By The Numbers By The Numbers

28

percent

of Latino kids suffer four or more adverse childhood experiences (ACES).

Share your thoughts